In this GEN webinar, our expert speakers will explore cutting-edge drug discovery techniques for target deconvolution and multiplex target discovery.
Poster presentation highlights promising results from Phase 1b/2 TENACITY-01 study of CTD402 in T-Cell and myeloid leukemiasFindings underscore ...
ACTO, a leader in AI-first field excellence solutions for life sciences and a Veeva Product Partner and member of the Veeva ...
Discover why Structure Therapeutics Inc. is rated Strong Buy after positive Aleniglipron phase 2b obesity data. Click for ...
Preliminary clinical evidence of Lisaftoclax overcoming venetoclax resistance in myeloid malignancies with a 31.8% overall response rate(ORR) in this subgroup of patients; 80% ORR ...
Imviva Biotech, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, today presented clinical data for CTD402, its investigational allogeneic anti-CD7 CAR ...
Presented in an oral session at the 67th American Society of Hematology Annual Meeting & Exposition ...
This prevents criss-crossing of trucks, eliminates unauthorized diversions, and ensures that trucks only enter Terminals for ...
Data show deep, durable responses in the 50 million cell dose level cohort; initial data suggest substantial early improvement in three patients ...
Kelonia Therapeutics' KLN-1010 has shown promising early results in a phase 1 trial for relapsed or refractory multiple ...
Big Easy SEO incorporated mobile marketing into its digital marketing service operations in early 2025. The service category falls within the company’s internet marketing division. Mobile marketing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback